Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Top Cited Papers
- 1 January 2020
- journal article
- research article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 75 (1), 84-104
- https://doi.org/10.1053/j.ajkd.2019.06.009
Abstract
No abstract availableKeywords
Funding Information
- Alexion
- Astellas
- AstraZeneca
- Bayer
- Boehringer-Ingelheim
- Gilead
- Ironwood
- Kyowa Hakko Kirin
- Merck
- Novartis
- Novo-Nordisk
- National Institutes of Health
- Siemens
- NIH
- NKF
- Tufts Medical Center
- AbbVie
- AstraZeneca
- Boehringer Ingelheim
- Gilead
- Merck (all
- NKF
- NKF
- AbbVie
- Boehringer Ingelheim
- GSK
- Novo Nordisk
- AbbVie
- Bayer
- Ipsen
- Sanofi-Genzyme
This publication has 49 references indexed in Scilit:
- Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)BMC Medical Research Methodology, 2012
- Proteinuria as a surrogate end point—more data are neededNature Reviews Nephrology, 2012
- Trial Quality in Nephrology: How Are We Measuring Up?American Journal of Kidney Diseases, 2011
- The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference reportKidney International, 2011
- The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysisClinical Therapeutics, 2009
- Current Issues in Measurement and Reporting of Urinary Albumin ExcretionClinical Chemistry, 2009
- Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin systemJournal Of Hypertension, 2007
- Blood pressure as an example of a biomarker that functions as a surrogateThe AAPS Journal, 2006
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?Kidney International, 1990